AQP4 and neuromyelitis optica: Compared with AQP4-positivity patients, serum MOG antibodies do have a distinct clinical phenotype from AQP4-positivity NMO that is characterized by fewer relapses, a better clinical outcome, and a wider spectrum of MRI features, which may suggest a sort of disease distinct from NMO or MS [37–39].